Literature DB >> 29506673

Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.

Dan Høgdall1, Monika Lewinska2, Jesper B Andersen3.   

Abstract

Cholangiocarcinoma (CCA) is a dismal disease which often is diagnosed at a late stage where the tumor is locally advanced, metastatic, and, as a result, is associated with low resectability. The heterogeneity of this cancer type is a major reason why the majority of patients fail to respond to therapy, and surgery remains their only curative option. Among patients who undergo surgical intervention, such tumors typically recur in 50% of cases within 1year. Thus, CCA is among the most aggressive and chemoresistant malignancies. CCA is characterized by marked tumor reactive stroma, a fibrogenic connective tissue which surrounds and infiltrates the tumor epithelium. This desmoplastic environment presents a clinical challenge, limiting drug delivery and supporting the growth of the tumor mass. In this review we attempt to highlight key pathways involved in cell to cell communication between the tumor epithelium and stroma, the immune components, and opportunities for novel strategies to improve patient outcome.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29506673     DOI: 10.1016/j.trecan.2018.01.007

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  25 in total

1.  Construction of a competing endogenous RNA network related to the prognosis of cholangiocarcinoma and comprehensive analysis of the immunological correlation.

Authors:  Ning Wang; Yinghui Zhou; Zhifan Zuo; Ruoyu Wang; Jing Li; Tao Han; Bin Yang
Journal:  J Gastrointest Oncol       Date:  2021-10

Review 2.  Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms.

Authors:  Mihailo Miljanic; Anna Capasso; Todd A Triplett; S Gail Eckhardt; Kyaw L Aung
Journal:  J Immunother Precis Oncol       Date:  2020-02-10

3.  Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer.

Authors:  Gu-Wei Ji; Ke Wang; Yong-Xiang Xia; Jin-Song Wang; Xue-Hao Wang; Xiang-Cheng Li
Journal:  Ann Surg Oncol       Date:  2020-11-23       Impact factor: 5.344

Review 4.  Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.

Authors:  Juan Wang; Sumera Ilyas
Journal:  Expert Opin Investig Drugs       Date:  2020-12-28       Impact factor: 6.206

Review 5.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

6.  IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Authors:  Stephen P Hack; Wendy Verret; Sohail Mulla; Bo Liu; Yulei Wang; Teresa Macarulla; Zhenggang Ren; Anthony B El-Khoueiry; Andrew X Zhu
Journal:  Ther Adv Med Oncol       Date:  2021-07-31       Impact factor: 8.168

7.  Identification of a Pan-Gamma-Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma.

Authors:  Colm J O'Rourke; Matthias S Matter; Chirag Nepal; Rui Caetano-Oliveira; Phuongnga T Ton; Valentina M Factor; Jesper B Andersen
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.298

Review 8.  Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.

Authors:  Taek Chung; Young Nyun Park
Journal:  Front Med (Lausanne)       Date:  2022-03-31

9.  Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma.

Authors:  Qianfei Zhang; Chi Ma; Yi Duan; Bernd Heinrich; Umberto Rosato; Laurence P Diggs; Lichun Ma; Soumen Roy; Qiong Fu; Zachary J Brown; Simon Wabitsch; Vishal Thovarai; Jianyang Fu; Dechun Feng; Benjamin Ruf; Linda L Cui; Varun Subramanyam; Karen M Frank; Sophie Wang; David E Kleiner; Thomas Ritz; Christian Rupp; Bin Gao; Thomas Longerich; Alexander Kroemer; Xin Wei Wang; Mathuros Ruchirawat; Firouzeh Korangy; Bernd Schnabl; Giorgio Trinchieri; Tim F Greten
Journal:  Cancer Discov       Date:  2020-12-15       Impact factor: 38.272

10.  Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.

Authors:  Julia S Johansen; Jesper B Andersen; Dan Høgdall; Colm J O'Rourke; Christian Dehlendorff; Ole F Larsen; Lars H Jensen; Astrid Z Johansen; Hien Dang; Valentina M Factor; Mie Grunnet; Morten Mau-Sørensen; Douglas V N P Oliveira; Dorte Linnemann; Mogens K Boisen; Xin W Wang
Journal:  Clin Cancer Res       Date:  2020-09-15       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.